Testing an immune-targeting drug by direct injection into tumors
Part of Cancer clinical trials.
This Phase 1/2 trial tests T3P, a new treatment given directly into reachable solid tumors, to see if it is safe and can help shrink tumors. It is for adults with advanced cancers when no curative treatment is available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid cancer that can’t be fully removed and you don’t have a better treatment option
- You have at least one “measurable” tumor spot that can be injected directly into it (visible/palpable, or seen on ultrasound)
- You are 18 years or older, and you can sign consent and follow study instructions
- Your overall health is fairly good (performance status 0 or 1) and you’re expected to live at least 12 weeks
- Any effects from prior treatment or surgery must be mostly gone (back to baseline or Grade 0–1, except hair loss)
- You need enough iron stores and your blood/organ tests must be within allowed ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (called MEDI5752) for people with certain solid tumors that have a special immune feature called 'mature tertiary lymphoid structures.' The drug is designed to help your immune system fight the cancer more effectively. You may be able to join even if you haven't had immunotherapy before, or if you had it and it stopped working after a while.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This Phase 1 trial tests a cancer vaccine (VAX014) injected directly into a tumor, given alone at first and then with an immune checkpoint medicine (nivolumab or pembrolizumab). It aims to see how well this approach is tolerated and may help shrink advanced solid tumors after other treatments stopped working.
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
This study tests a new treatment using your body's own immune cells (called tumor-infiltrating lymphocytes) that are taken from your tumor, grown in a lab, and then put back into you. It's for people with advanced solid tumors who have run out of standard options.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.